The central achievement of the work is the determination of cryo-electron microscopy structures of human NLRP6 in two distinct conformational states: one in which ATP is bound within the nucleotide-binding domain, and one in which that domain is unoccupied. Capturing a signaling protein of this complexity in more than one state is a technical tour de force. NLRP6 belongs to the NOD-like receptor family, whose members are built from a modular architecture that includes a pyrin domain for downstream signaling, a central nucleotide-binding oligomerization domain, or NBD, and a leucine-rich repeat region that is thought to sense activating cues. In the resting state, these modules are folded against one another in a self-suppressed arrangement; upon activation, the protein must rearrange dramatically to oligomerize and recruit downstream adaptors. Cryo-EM is uniquely suited to visualizing both the compact monomeric states and the extended oligomeric assemblies that NLR-family proteins adopt along this trajectory.

What the structures reveal is that ATP is not merely a passive occupant of the nucleotide-binding pocket but an active participant in the regulatory logic of the receptor. By binding within the NBD, ATP stabilizes a conformation of NLRP6 in which the domains are locked together in an arrangement that precludes the transitions required for inflammasome assembly. In effect, the nucleotide acts as a molecular latch. The comparison between the ATP-bound and ATP-unbound conformations allowed the researchers to trace precisely which intramolecular contacts shift when the nucleotide engages the pocket, and how those shifts propagate through the protein to restrain the regions that would otherwise mediate self-association and filament formation.

This finding carries considerable conceptual weight because nucleotide binding has historically been viewed primarily through the lens of activation in this protein family. Many NLR proteins require ATP binding or hydrolysis for their oligomerization and signaling functions, and ATP or its analogues have often been used experimentally to promote the assembly of inflammasome complexes in vitro. The new structures of NLRP6 invert that expectation for this particular receptor, identifying ATP as a stabilizer of the inactive, monomeric state rather than a driver of oligomerization. The work thus adds an important nuance to the general model of NLR regulation: the effect of nucleotide binding is not uniform across the family, and it must be understood receptor by receptor, in structural terms, rather than assumed.

The mechanistic detail extracted from the structures is substantial. By comparing the two conformational states at high resolution, Cui and colleagues could identify the specific structural elements that respond to ATP occupancy. These include regions of the NBD that reposition relative to the adjacent regulatory domains, contacts that either form or dissolve depending on whether the nucleotide is present, and hinge-like segments whose mobility governs whether the protein can escape its autoinhibited fold. Such residue-level information is precisely what is needed to design targeted experiments, and indeed the study is framed around structure-guided biochemical validation of the observed interactions, a standard that has become the norm for mechanistic structural biology of innate immune receptors.

The broader context of this work is the intense interest in the NLRP family of inflammasome sensors, and in NLRP3 in particular, as drug targets. Overactive inflammasome signaling has been implicated in a wide range of human diseases, from gout and atherosclerosis to neurodegeneration and inflammatory bowel disease. NLRP6, which is especially prominent in epithelial tissues such as the intestine, has emerged as a key regulator of mucosal immunity and of the interplay between the host and the microbiome. Understanding how NLRP6 is held in its inactive state therefore has implications that extend well beyond basic receptor biology, touching on the architecture of the intestinal barrier and the maintenance of a healthy relationship with the microbial communities that inhabit it.

From a structural biology standpoint, the study also exemplifies the current maturity of cryo-electron microscopy as a method for dissecting regulatory mechanisms in immune proteins. A decade ago, obtaining structures of a large, flexible, multidomain receptor in even one state would have been a career-defining effort. Today, as this work demonstrates, it is feasible to capture the same protein in multiple functional states and to compare them directly, transforming what was once a static portrait of a protein into something closer to a molecular film. The two NLRP6 structures together form precisely such a comparison: one frame showing the nucleotide-engaged, inhibited receptor, another showing the conformation from which activation must proceed.

The identification of ATP as an endogenous inhibitor also raises intriguing questions about how intracellular nucleotide levels tune inflammasome sensitivity. Cells experience fluctuations in ATP availability under stress, during metabolic shifts, and in the course of infection. If ATP occupancy of the NLRP6 nucleotide pocket keeps the receptor in a signaling-competent-off state, then changes in cellular energy status could, in principle, translate into changes in the threshold at which NLRP6 fires. Whether such metabolic regulation operates in living cells, and how it intersects with the other inputs that NLRP6 senses, are questions that the structural work now makes experimentally accessible. The structures provide a concrete physical hypothesis that cell biological and biochemical studies can test directly.

For the growing community of researchers attempting to develop inflammasome-directed therapeutics, the study offers a template. Drugs that stabilize an autoinhibited conformation, or that mimic the effect of ATP binding, could in principle dampen pathological NLRP6 signaling. Conversely, understanding exactly which interactions must break for activation to occur points to where small molecules might lock the receptor open, should augmentation of NLRP6-dependent immunity ever be clinically desirable. The structural map produced by Cui and colleagues converts those goals from abstract ambitions into chemically addressable problems, listing the pockets, interfaces, and conformational switches that any future drug would need to engage. In a field where the therapeutic stakes are high and the molecular targets are notoriously difficult to control, that kind of precision is exactly what progress looks like.

Subject of Research: Structural mechanism of ATP-mediated inhibition of the human NLRP6 inflammasome revealed by cryo-electron microscopy.

Article Title: Structural mechanisms for ATP-mediated inhibition of human NLRP6 inflammasome

Article References: Cui, Z., Sheng, Q., Son, M., Goo, Y. A., & Shen, C. (2026). Structural mechanisms for ATP-mediated inhibition of human NLRP6 inflammasome. Nature Structural & Molecular Biology. https://doi.org/10.1038/s41594-026-01878-5

Image Credits: AI Generated

DOI: 10.1038/s41594-026-01878-5

Keywords: NLRP6, inflammasome, ATP, cryo-EM, innate immunity, NOD-like receptors, structural biology, inflammation, NBD, immune regulation, intestinal immunity, autoinhibition

The review, authored by Isabela Gontijo, Mariana Camurça and José Roberto Kfoury of the University of São Paulo, systematically dissects why IDO1-targeted drugs have underperformed in the clinic. The most famous failure was epacadostat, which, despite robustly lowering kynurenine when combined with pembrolizumab in a randomized phase 2 study in metastatic non-small-cell lung cancer, did not improve objective response rates over pembrolizumab alone. The authors argue that such disappointing results should not be read as evidence that the drug failed to engage its target. Instead, they propose, IDO1 operates within a distributed metabolic network in which substrate availability, alternative enzymes, non-enzymatic signaling, cell-specific metabolic programs, downstream receptors and even the gut microbiome can each sustain tryptophan-dependent immunoregulation after the primary enzyme is pharmacologically silenced.

To appreciate the scale of the problem, it helps to understand how IDO1 works. The enzyme is a cytosolic, heme-containing oxidoreductase expressed in dendritic cells, macrophages, stromal cells and cancer cells. Its transcription is induced when interferon-gamma binds its receptor, activating JAK1 and JAK2 kinases that phosphorylate STAT1. Phosphorylated STAT1 dimers, known as gamma-activated factor, translocate to the nucleus and bind gamma-activated sites in the IDO1 promoter, while a secondary wave of interferon regulatory factor 1 amplifies the signal through interferon-stimulated response elements. Once made, IDO1 is catalytically active only when its heme iron is in the reduced ferrous state, allowing it to cleave the indole ring of L-tryptophan and generate N-formyl-L-kynurenine, which arylformamidase rapidly converts to L-kynurenine. This step is the rate-limiting entry point of tryptophan into the kynurenine pathway, which ultimately feeds de novo NAD+ biosynthesis.

The downstream consequences of this reaction extend well beyond substrate consumption. Tryptophan depletion activates the GCN2 integrated stress response while dampening mTORC1 signaling, the nutrient-sensing hub that drives protein translation, cell-cycle progression and clonal expansion in activated T lymphocytes. Meanwhile, accumulated kynurenine acts as an endogenous ligand for the aryl hydrocarbon receptor, which sheds its cytoplasmic chaperone complex, enters the nucleus, pairs with ARNT and switches on a tolerogenic transcriptional program in antigen-presenting and myeloid cells. This favors regulatory T-cell differentiation and blunts effector immunity, although the review is careful to note that AHR biology is context dependent: in some settings, such as resident-memory CD8-positive T cells and natural killer cells, AHR activity actually enhances antitumor function. IDO1 also has a second, entirely non-enzymatic identity. In TGF-beta-conditioned dendritic cells, the enzyme is phosphorylated on immunoreceptor tyrosine-based inhibitory motifs by the Src-family kinase Fyn, recruiting the phosphatases SHP-1 and SHP-2 and triggering non-canonical NF-kappa-B signaling through p52/RelB complexes, a positive feedback loop that sustains long-term immune tolerance independently of catalysis.

Against this backdrop, the review catalogs a series of compensatory routes that survive IDO1 blockade. The first is enzymatic redundancy. Tryptophan 2,3-dioxygenase 2, or TDO2, is a hepatic, glucocorticoid-regulated heme enzyme that catalyzes exactly the same initial reaction as IDO1, oxidizing tryptophan to N-formyl-L-kynurenine. Because selective IDO1 inhibitors leave the substrate itself untouched, any cell expressing active TDO2 can simply absorb the surplus tryptophan and feed it back into the kynurenine pathway, preserving kynurenine-dependent AHR signaling without any restoration of IDO1 activity. Its paralog IDO2, encoded next to IDO1, has weak catalytic efficiency but may contribute through membrane-associated signaling functions of its own. This mechanistic logic underlies the development of dual IDO1/TDO2 inhibitors such as M4112 and SHR9146, which are designed to close both enzymatic entry points simultaneously.

A second form of compensation is metabolic rerouting. When IDO1-dependent consumption falls, more tryptophan remains available to competing enzymes, including tryptophan hydroxylase 1 and 2, which commit the amino acid to the serotonergic pathway instead. The resulting surge in 5-hydroxytryptophan and serotonin does not simply vanish into a metabolic dead end: serotonin is itself an extracellular signaling molecule, sensed by a family of G-protein-coupled receptors and the ion-channel receptor 5-HT3 on monocytes, macrophages, dendritic cells and lymphocytes, where it modulates cytokine production, migration and differentiation. Serotonin can be further converted to melatonin through AANAT and ASMT, adding another layer of immunomodulatory chemistry. Clinical evidence supports this rewiring: in ovarian cancer patients treated with an IDO1 inhibitor, tumor metabolic adaptation toward the serotonin pathway was documented and found to constrain antitumor immune responses.

A third route runs through IL4I1, a secreted FAD-dependent amino acid oxidase induced by interleukin-4 that oxidizes tryptophan to indole-3-pyruvic acid, releasing ammonia and hydrogen peroxide. Because this chemistry is fundamentally different from heme-dependent dioxygenation, IDO1 inhibitors have no direct effect on it. Yet the indole metabolites IL4I1 produces, including indole-3-aldehyde, are potent AHR ligands, meaning the pathway bypasses the kynurenine step entirely while converging on the same tolerogenic receptor. Recent studies have linked IL4I1/AHR signaling to macrophage polarization in allergic rhinitis and to anti-inflammatory programs in cytokine-primed muscle stem cells, underscoring how a single receptor can be fed by multiple, pharmacologically independent metabolic tributaries.

The review also elevates compensation from the single-cell to the tissue level. Tryptophan transporters such as LAT1 and SLC7A11 are distributed unevenly across cell types, so when IDO1-expressing cells stop consuming tryptophan, neighboring cells with high transporter activity act as alternative metabolic sinks, redirecting the shared substrate according to their own enzymatic repertoires. Single-cell RNA sequencing in inflammatory intestinal tissue has revealed sharply different tryptophan-metabolic profiles among macrophages, fibroblasts and epithelial cells, while work in macrophages shows that efferocytosis induces a coordinated program of tryptophan uptake, IDO1 expression and kynurenine production that aids tissue resolution. In this non-cell-autonomous model, substrate consumption, metabolite production and metabolite sensing can all occur in different compartments of the same tissue, which means that inhibiting one enzymatic source may merely reshuffle the cellular geography of tryptophan metabolism rather than extinguishing its outputs.

Perhaps the most surprising player is the gut microbiome. Commensal bacteria wielding tryptophanases, aminotransferases and reductases convert dietary tryptophan into a diverse library of indoles, including indole-3-aldehyde, indole-3-lactic acid, indole-3-acetic acid and indole-3-propionic acid, many of which activate AHR in epithelial and immune cells. Landmark work by Zelante and colleagues showed in IDO1-deficient mice that microbiota-derived catabolites engage AHR and balance mucosal immunity through interleukin-22, and more recent studies demonstrate that lactic acid bacteria are particularly prolific producers of these ligands. Microbial compensation is not uniformly immunosuppressive: cooperative metabolism between Lactobacillus johnsonii and Clostridium sporogenes boosts indole-3-propionic acid, which promotes H3K27 acetylation at the Tcf7 super-enhancer and maintains progenitor exhausted CD8-positive T cells, thereby enhancing the efficacy of anti-PD-1 therapy across multiple cancer models. The microbiome, in other words, can either restore immune suppression or sharpen antitumor immunity, depending on which community members dominate.

The translational message of the review is a shift from enzyme-specific inhibition to network-based regulation. The authors draw a sharp distinction between target engagement, which merely confirms that IDO1 catalysis has been suppressed, and network suppression, which asks whether the broader biological output has actually fallen. Clinical data reinforce the point: in a phase 1/2 study of the irreversible inhibitor linrodostat combined with nivolumab, kynurenine fell across patient groups regardless of response, while therapeutic benefit associated instead with an interferon-gamma transcriptional signature and, in non-melanoma cohorts, with the combination of low TDO2 expression and high interferon-gamma signaling. Patient stratification in head and neck cancer likewise showed benefit only in subgroups with high baseline IDO1 RNA and context-specific immune signatures. The authors argue that future trials should pair serial plasma metabolomics with tissue-resolved assessment of IDO1, TDO2 and IL4I1 expression, AHR-responsive transcriptional markers and stool metagenomics, using adaptive designs that identify which compensatory node dominates in each patient. Emerging tools such as IDO1-targeting PROTACs, which degrade the protein and thereby disrupt both its catalytic and non-enzymatic signaling functions, may widen the mechanistic reach of treatment, but even protein removal cannot touch TDO2, IL4I1, microbial metabolism or downstream AHR activity. The lesson is sobering and clarifying at once: IDO1 is not a switch but one node in a dynamic, redundantly wired metabolic network, and effective immunometabolic therapy will require mapping exactly where compensation lives in each patient before deciding where to strike.

Subject of Research: Compensatory tryptophan metabolism and immune regulation pathways activated following IDO1 enzyme inhibition

Article Title: Compensatory pathways in tryptophan metabolism and immune regulation following IDO inhibition

Article References: Gontijo, I., Camurça, M., & Kfoury, J. R. (2026). Compensatory pathways in tryptophan metabolism and immune regulation following IDO inhibition. Molecular Biology Reports, 53(1), Article 1567. https://doi.org/10.1007/s11033-026-12707-9

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12707-9

Keywords: IDO1, tryptophan metabolism, kynurenine pathway, TDO2, IL4I1, aryl hydrocarbon receptor, immunotherapy resistance, epacadostat, gut microbiome, indole metabolites, serotonin pathway, immune regulation

The work focuses on ILC1 (innate lymphoid cells type 1), which act as rapid first responders against stressed or transformed cells. When the liver becomes lipid-laden, immune function can degrade, impairing the ability of ILC1 cells to maintain homeostasis. The study suggests ASB2 restores a healthier immune-metabolic balance, allowing ILC1 to remain fit and responsive.

Mechanistically, the team links ASB2 activity to pathways controlling lipid handling, reducing fat deposition and lowering the metabolic stress that normally compromises immune cell performance. This matters because lipid overload can alter signaling networks that govern cytokine programs and survival, pushing ILC1 cells toward dysfunction.

To test causality, the researchers manipulated ASB2 levels in mouse liver contexts and then assessed ILC1 homeostasis and function using immunological readouts. They observed that boosting ASB2 improved markers consistent with ILC1 fitness, while dampening ASB2 had the opposite effect, correlating with worse tumor control.

In tumor-challenge settings, ASB2’s lipid-suppressing role translated into measurable anti-tumor immunity. Enhanced ILC1 readiness supported stronger immune surveillance and improved outcomes compared with conditions that favored lipid accumulation.

The authors emphasize that the findings position ASB2 as a metabolic checkpoint connecting tissue lipid states to innate immune stability. This reframes anti-cancer strategies by suggesting that correcting organ-level metabolism can actively sustain the effectiveness of innate immune cells.

Overall, the study highlights a viral-science-worthy concept: immunotherapy may benefit from coupling immune modulation with metabolic rewiring. If similar mechanisms operate in humans, ASB2-linked pathways could inspire targeted interventions for liver-associated cancers.

Such an approach could be especially relevant where tumors exploit metabolic environments to blunt immunity. By turning down lipid accumulation, ASB2 may remove a barrier that ILC1 cells face inside the liver microenvironment.

Subject of Research: Liver metabolism and innate immune regulation (ILC1) in anti-tumor immunity

Article Title: ASB2 inhibits lipid accumulation to promote ILC1 homeostatic fitness and anti-tumor immunity in the mouse liver

Article References: Bao, B., Wang, X., Chen, Y. et al. ASB2 inhibits lipid accumulation to promote ILC1 homeostatic fitness and anti-tumor immunity in the mouse liver. Nat Commun (2026). https://doi.org/10.1038/s41467-026-75517-4